Navigation Links
Pathwork Diagnostics Announces Key Additions to Management Team
Date:10/8/2008

CFO and VP of US Sales Bring Industry Expertise to Pathwork Following FDA

Clearance and $20M Fundraising Round

SUNNYVALE, Calif., Oct. 8 /PRNewswire/ -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, announced today the appointment of two key positions within the company's management team, Fletcher Payne as Chief Financial Officer and Mark McDonough as Vice President of US Sales. These professionals bring over 20 years of industry expertise in their respective positions to Pathwork.

"Having Fletcher and Mark on the Pathwork management team will be a great asset moving forward," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "Both have proven track records in helping emerging companies grow efficiently and achieve results."

Pathwork's new CFO, Fletcher Payne, a graduate of UC Berkeley's Haas School of Business with a BS in Business Administration, joins Pathwork from Plexxikon Inc., a biopharmaceutical company where he served as a VP and CFO. Payne will lead the financial team, implement processes to support commercial growth and develop the overall financial strategy. Payne has over 20 years of business and financial experience, in both start-up and Fortune 500 companies. Prior to Plexxikon, he worked for Rinat Neuroscience, Dynavax Technologies, Cell Genesys, Sun Microsystems and IBM.

Mark McDonough joins Pathwork as Vice President of US Sales from US LABS, a division of Laboratory Corporation of America. With over 10 years of cancer diagnostics and reference laboratory experience, Mark will be responsible for the strategic and tactical sales initiatives at Pathwork. Prior to his time at US LABS, McDonough held various sales and sales management roles at Ventana Medical Systems and served as a Navigator and Communications Officer in the United States Navy. McDonough is a graduate of Miami University of Ohio with a BS in Finance.

About Pathwork Diagnostics

Pathwork Diagnostics, Inc., based in Sunnyvale, Calif., develops and commercializes high-value molecular diagnostics for oncology. The company's first test to market -- the Pathwork(R) Tissue of Origin Test -- utilizes proprietary analytics and a companion Pathchip(R) microarray, which runs on the proven Affymetrix GeneChip(R) System. The test aids in determining a hard-to-identify tumor's origin so that standard-of-care, cancer-specific treatment can begin. The test is FDA-cleared as an in vitro diagnostic kit, while a functionally equivalent version of the test is also available through the CLIA-certified Pathwork(R) Diagnostics Laboratory. For more information, call 1.877.808.0006 or visit http://www.pathworkdx.com.

Pathwork, Pathchip, Pathwork Diagnostics, and the Pathwork Diagnostics logo are trademarks or registered trademarks of Pathwork Diagnostics, Inc. Other names may be the trademarks of their respective owners.


'/>"/>
SOURCE Pathwork Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pathwork Diagnostics Closes $20M Financing
2. Pathwork(R) Diagnostics Launches Genomics-Based Test For Hard-To-Identify Tumors Through Its CLIA-Certified Laboratory
3. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
4. InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List
5. Fujirebio Diagnostics Named One of the Best Places to Work in Pennsylvania
6. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
7. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
8. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
9. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
10. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
11. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):